Novartis

Novartis gets a boost in blockbuster multiple sclerosis race with Roche
Endpoints
Mon, 02/24/20 - 10:41 am
Novartis
MS
multiple sclerosis
FDA
priority reviews
Arzerra
With supply tight, Novartis readies gene therapy plant for production
BioPharma Dive
Fri, 02/21/20 - 11:45 pm
Novartis
Zolgensma
spinal muscular atrophy
drug manufacturing
New Meds Set to Reshape US CNS and oncology Markets
Xconomy
Tue, 02/18/20 - 08:36 pm
CNS
oncology
cancer
Clarivate Analytics
Biohaven
rimegepant
Novartis
OMB-157
Former Novartis exec pleads guilty to generic price fixing
Endpoints
Tue, 02/18/20 - 10:25 am
Novartis
Sandoz
price fixing
generics
DOJ
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Novartis plots cardio trial in UK as London HQ opens
Pharmaforum
Wed, 02/12/20 - 10:52 am
Novartis
clinical trials
London
UK
inclisiran
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Tue, 02/11/20 - 10:28 am
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
BioSpace
Sun, 02/9/20 - 04:01 pm
MS
multiple sclerosis
Biogen
Sanofi
Active Biotech
Mylan
Novartis
Adamas
Are Novartis and Regeneron seeing the same thing?
BioPharma Dive
Fri, 02/7/20 - 11:42 pm
Novartis
Regeneron
physicians
Eylea
Beovu
Novartis faces criticism over Zolgensma ‘health lottery’
PM Live
Thu, 02/6/20 - 11:51 pm
Novartis
SMA
gene therapy
Zolgensma
lottery
Sandoz Completes Acquisition of Aspen's Japanese Operations
BioSpace
Sat, 02/1/20 - 11:49 pm
Sandoz
Aspen Global
Japan
M&A
Novartis
Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin
Fierce Pharma
Thu, 01/30/20 - 09:17 pm
Novartis
Sandoz
United Therapeutics
Remodulin
Vas Narasimhan wants Novartis to have a big focus on China. Here’s what that looks like
Endpoints
Thu, 01/30/20 - 10:49 am
Novartis
China
Pharma CEOs
Vas Narasimhan
Novartis gives up on Advair generic, leaving Mylan as sole competitor
BioPharma Dive
Wed, 01/29/20 - 11:52 pm
Novartis
generics
Advair
Mylan
Novartis Earnings Narrowly Top; Drug Giant Rises In Buy Zone
Investors Business Daily
Wed, 01/29/20 - 10:38 am
Novartis
earnings
Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter
Stat
Wed, 01/29/20 - 10:37 am
Novartis
Zolgensma
SMA
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Tue, 01/28/20 - 11:09 am
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Life after Novartis: Jimenez joins board of Bayer-backed cell therapy startup
Fierce Biotech
Tue, 01/28/20 - 11:03 am
Joe Jimenez
Novartis
Bayer
Century Therapeutics
cell therapy
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Endpoints
Fri, 01/24/20 - 10:30 am
ICER
sickle cell disease
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
Emmaus Life Sciences
Endari
5 biopharmas to watch as the decade's last earnings kick off
BioPharma Dive
Wed, 01/22/20 - 11:06 am
earnings
Novartis
Biogen
Eli Lilly
Global Blood Therapeutics
Bluebird Bio

Pages